RETINA: Reliable Eye Tracking In Neurocognitive Assessment

An objective, rapid “digital vital sign” for cognition using synchronized eye tracking, pupillometry, and response-time metrics

A man sitting at a desk, holding his head in frustration, surrounded by a large stack of papers, with a woman standing nearby holding a clipboard while observing him.

Cognitive function is difficult to measure objectively

Across research, clinical trials, and applied settings, cognition is still assessed primarily through subjective testing, coarse screening tools, or time-intensive batteries. These approaches often lack sensitivity to subtle impairment or change, are difficult to scale, and can be poorly suited to repeated or longitudinal measurement.

A woman with curly hair wearing a virtual reality headset, sitting on a couch in a bright room with large windows, holding VR controllers, with digital graphics of an eye, a heart rate graph, and a line chart projected in front of her.

RETINA captures objective cognitive signals in minutes

Eye movements: attention, executive control, inhibition, and processing dynamics

Pupil responses: cognitive load and autonomic modulation

Manual responses: reaction time and accuracy under controlled cognitive demand

Standardized cues: designed to probe specific neurocognitive systems

Close-up of a human eye with brown iris, visible eyelashes, and detailed skin texture around the eye.

Designed for sensitivity, speed, and scalability

Sensitive to targeted cognitive impairment and change, not just gross deficits

Rapid and repeatable, enabling longitudinal and interventional measurement

Objective by design, eliminating confounds and reducing dependence on subjective scoring

A woman wearing a virtual reality headset and holding motion controllers, sitting in a beige armchair, with a healthcare professional or researcher sitting across from her, taking notes on a tablet, in a bright room with a large plant and bookshelf in the background.

Applications across research and applied brain health.

Neurocognitive research: objective endpoints for studies of attention, executive function, and processing speed

Biopharma clinical trials: sensitive digital neurocognitive endpoints for intervention effects

Occupational and operational readiness: scalable assessment in high-performance or safety-critical settings

A doctor explaining a virtual reality treatment to a male patient in a hospital room.

Clinical Applications Following Regulatory Clearance

General Cognitive Assessment: Objective measures of attention, processing speed, and executive function.

Concussion / TBI: Quantitative tracking of cognitive impairment and recovery over time.

Mild Cognitive Impairment and Dementia: Sensitive monitoring of cognitive change and disease progression.

Multiple Sclerosis: Objective assessment of cognitive function and treatment-related change.

Alzheimer’s Disease: Neurocognitive metrics to support evaluation and longitudinal monitoring.

ADHD: Measurement of attentional control and executive function dynamics.

Other Neurological Conditions: Expandable use across conditions involving cognitive performance.

A wooden desk with an open handbook, a stack of papers labeled "Patent Application Documentation," a pen, and sticky notes, with a bookshelf and window in the background.

Built on a strong scientific foundation.

Integrates well-established cognitive paradigms

Patented core technology

15 years of peer-reviewed scientific validation

Ongoing applied studies